It has been shown that the fractal scaling properties of heart rate dynamics, in healthy aging, differ from that seen in heart disease and this favors the use of fluctuation measures as diagnostic tools. The purpose of this study was to evaluate the fractal heart rate dynamics in adults with Down syndrome (DS) under different physiological conditions (rest, exercise and post-exercise recovery) and compare their responses with those of nondisabled individuals. Fourteen participants (10 males; and 4 females) with DS and 13 nondisabled (9 males, and 4 females) controls performed maximal and submaximal treadmill tests with metabolic and heart rate measurements. Detrended fluctuation analysis was performed on the last 256 consecutive R-R intervals obtained under the following conditions: (1) standing rest, (2) submaximal treadmill exercise and (3) standing post-exercise recovery. Participants with DS presented lower chronotropic response than controls to peak and submaximal exercise (p<0.05). The short-term scaling exponent (α(1)) was greater in the DS group at rest (1.29±0.06 vs 1.07±0.08), during exercise (1.24±0.09 vs 0.99±0.08) and recovery (1.31±0.06 vs 1.21±0.06) (p<0.05). Furthermore, the fractal scaling distance score (I1-α(1)I) of participants with DS was also greater than that of controls under each physiological condition (p<0.05). This confirmed their greater fractal distance from the healthy value of 1.0. In conclusion, adults with DS show a breakdown of scale-invariant organization in heart rate dynamics towards Brownian noise and this is similar to that described in healthy aging.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.autneu.2010.12.007 | DOI Listing |
Am J Physiol Heart Circ Physiol
January 2025
Comenius University Bratislava, Faculty of Pharmacy, Department of Pharmacology and Toxicology, Bratislava, Slovakia.
Cholinesterase (ChE) inhibitors are under consideration to be used in the treatment of cardiovascular pathologies. A prerequisite to advancing ChE inhibitors into the clinic is their thorough characterization in the heart. The aim here was to provide a detailed analysis of cardiac ChE to understand their molecular composition, localization, and physiological functions.
View Article and Find Full Text PDFUltrasound J
January 2025
Health Sciences North Research Institute, Sudbury, ON, Canada.
The duration of mechanical systole-also termed the flow time (FT) or left ventricular ejection time (LVET)-is measured by Doppler ultrasound and increasingly used as a stroke volume (SV) surrogate to guide patient care. Nevertheless, confusion exists as to the determinants of FT and a critical evaluation of this measure is needed. Using Doppler ultrasound of the left ventricular outflow tract velocity time integral (LVOT VTI) as well as strain and strain rate echocardiography as grounding principles, this brief commentary offers a model for the independent influences of FT.
View Article and Find Full Text PDFClin Otolaryngol
January 2025
Department of Otorhinolaryngology-Head and Neck Surgery, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Introduction: Obstructive sleep apnoea (OSA) in children is associated with numerous adverse outcomes, including elevated blood pressure. While the associations between OSA, obesity, and autonomic dysfunction are recognised, the precise mechanisms linking these factors and their relationship with elevated blood pressure in children remain unclear.
Methods: This retrospective case series included 76 children with OSA.
Artif Organs
January 2025
Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA.
Background: GLP-1 RAs improve cardiometabolic outcomes in obese, diabetic, and heart failure patients. Data on the safety and efficacy of GLP-1 RA in advanced heart failure with durable LVAD is limited.
Objectives: To assess the safety and efficacy of GLP-1 RA in durable LVAD patients.
J Vet Intern Med
January 2025
Boehringer Ingelheim Pharma GmbH & Co., Ingelheim, Germany.
Background: Myxomatous mitral valve disease (MMVD) is frequently diagnosed in small breed dogs. Pimobendan oral solution has been developed to improve dosing accuracy in small and toy breed dogs.
Hypothesis/objectives: Demonstrate bioequivalence of pimobendan oral solution with pimobendan chewable tablets using a pharmacokinetic and a pharmacodynamic study in healthy purpose bred dogs.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!